Sabra Healthcare REIT (NASDAQ:SBRA) Announces Earnings Results

Sabra Healthcare REIT (NASDAQ:SBRA) released its quarterly earnings data on Monday. The real estate investment trust reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.05), FiscalAI reports. The business had revenue of $249.57 million during the quarter, compared to analyst estimates of $236.64 million. Sabra Healthcare REIT had a net margin of 7.78% and a return on equity of 2.56%. The company’s revenue was up 31.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.38 earnings per share.

Sabra Healthcare REIT Stock Up 0.9%

Sabra Healthcare REIT stock traded up $0.18 during trading on Wednesday, reaching $20.53. The stock had a trading volume of 239,731 shares, compared to its average volume of 2,660,454. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.95. The business has a 50 day moving average price of $19.85 and a 200 day moving average price of $19.97. The stock has a market cap of $5.25 billion, a PE ratio of 73.48, a P/E/G ratio of 1.79 and a beta of 0.68. Sabra Healthcare REIT has a 52-week low of $17.53 and a 52-week high of $22.77.

Sabra Healthcare REIT Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be paid a $0.30 dividend. The ex-dividend date is Friday, November 13th. This represents a $1.20 dividend on an annualized basis and a yield of 5.8%. Sabra Healthcare REIT’s payout ratio is currently 461.54%.

Analyst Upgrades and Downgrades

SBRA has been the subject of a number of recent analyst reports. Huntington assumed coverage on shares of Sabra Healthcare REIT in a research report on Thursday, September 10th. They set an “outperform” rating and a $23.00 price target for the company. Barclays reduced their price target on shares of Sabra Healthcare REIT from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 13th. Weiss Ratings raised shares of Sabra Healthcare REIT from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday. Citigroup restated a “market outperform” rating on shares of Sabra Healthcare REIT in a report on Wednesday, July 22nd. Finally, Wells Fargo & Company cut their target price on shares of Sabra Healthcare REIT from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Monday, October 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Sabra Healthcare REIT currently has an average rating of “Moderate Buy” and a consensus price target of $21.50.

Sabra Healthcare REIT News Roundup

Here are the key news stories impacting Sabra Healthcare REIT this week:

• Positive Sentiment: Sabra raised its 2026 EPS guidance to $1.54–$1.55, above the prior analyst consensus of $1.52, and increased the midpoint of normalized FFO guidance by $0.005 per share. Management also expects 7%–8% year-over-year earnings growth in 2026. Sabra Q3 adjusted FFO, revenue rise; 2026 guidance lifted
• Positive Sentiment: Third-quarter FFO came in at $0.41 per share, topping the $0.40 consensus estimate and rising from $0.38 a year earlier. Revenue of $249.6 million also exceeded expectations of about $236.6 million and increased 31.4% year over year. Sabra Healthcare tops Q3 FFO and revenue estimates
• Positive Sentiment: Senior-housing same-store occupancy reached 89.2%. Sabra is targeting 50% SHOP exposure by year-end 2027, signaling plans to expand its senior-housing operating portfolio. Sabra Health Care: 3 key takeaways for long-term investors
• Positive Sentiment: Huntington Securities initiated coverage with a “strong-buy” rating, adding a favorable analyst view. Huntington Securities stock recommendations
• Positive Sentiment: Sabra declared a quarterly dividend of $0.30 per share, equivalent to $1.20 annualized and a yield of about 5.9% based on the provided price data.
• Negative Sentiment: Third-quarter GAAP EPS was $0.11, missing the $0.16 consensus and down from $0.38 a year earlier. That earnings miss may temper the positive reaction to the FFO and revenue beats.

Insider Activity at Sabra Healthcare REIT

In other news, CEO Richard Matros sold 200,000 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $20.83, for a total value of $4,166,000.00. Following the transaction, the chief executive officer owned 1,657,686 shares in the company, valued at approximately $34,529,599.38. This represents a 10.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.09% of the company’s stock.

About Sabra Healthcare REIT

Sabra Healthcare REIT, Inc is a self-managed real estate investment trust that owns and invests in healthcare-related real estate. The company focuses primarily on properties used for skilled nursing and transitional care, senior housing, behavioral health, specialty hospitals and other healthcare services.

Sabra leases properties to healthcare operators and also provides capital through loans, joint ventures and other real estate investments. Its portfolio is designed to support a range of care settings, including facilities serving seniors, patients requiring rehabilitation and individuals receiving behavioral healthcare.

Founded in 2010 and headquartered in Irvine, California, Sabra has expanded through acquisitions, development investments and strategic transactions, including its 2017 combination with Care Capital Properties.